Pipeline
Gamma Delta T
Gamma delta (γδ) T cells are a unique subset of T lymphocytes that play a crucial role in immune surveillance and anti-tumor activity. Unlike conventional αβ T cells, γδ T cells recognize and attack cancer cells in an MHC-independent manner, making them an attractive candidate for allogeneic cell therapy. Our unmodified γδ T cell platform is designed to harness the natural cytotoxicity of these cells to target a range of solid and hematologic malignancies.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD001
​Glioblastoma
JY-GD002
Pancreatic cancer
JY-GD003
AML
JY-GD004
Hepatic cancer
JY-GD005
Lung cancer
JY-GD006
Metastatic TNBC
JY-GD001 (GBM)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD001
​Glioblastoma
Glioblastoma (GBM) is the most aggressive and common primary brain tumor, characterized by rapid growth, resistance to standard therapies, and a highly immunosuppressive tumor microenvironment. JY-GD001 is our unmodified allogeneic gamma delta T cell product being developed for the treatment of GBM. The goal is to enhance immune-mediated tumor clearance by overcoming the immunosuppressive nature of the brain tumor microenvironment. Our approach aims to offer a novel immunotherapeutic strategy for GBM patients who have limited treatment options following standard-of-care therapies. The development of JY-GD001 is progressing towards early-phase clinical trials, with a focus on safety, dosing, and efficacy evaluation.
JY-GD002 (Pancreatic Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD002
Pancreatic cancer
Pancreatic cancer is a highly lethal malignancy with poor prognosis, primarily due to late-stage diagnosis, aggressive tumor biology, and resistance to current therapeutic options. JY-GD002 is our unmodified allogeneic gamma delta T cell therapy for the treatment of pancreatic cancer. The aim is to leverage γδ T cells' innate ability to recognize and destroy pancreatic tumor cells while modulating the immune microenvironment to improve treatment outcomes. We are advancing JY-GD002 through preclinical and early clinical development, with the goal of establishing a novel immunotherapy for pancreatic cancer patients who have limited options after first-line treatments.
JY-GD003 (AML)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD003
AML
Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of immature myeloid cells, leading to bone marrow failure and systemic complications. JY-GD003 is our unmodified allogeneic gamma delta T cell product for the treatment of AML. The therapy is designed for patients who do not respond well to standard chemotherapy, with the aim of delaying or preventing the need for bone marrow transplantation. We are preparing to initiate clinical trials to evaluate the safety and efficacy of JY-GD003, with the ultimate goal of advancing this therapy towards regulatory approval and commercialization.
JY-GD004 (Hepatic Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD004
Hepatic cancer
Hepatic cancer is a highly aggressive malignancy with limited treatment options and poor prognosis, often due to late-stage diagnosis, rapid tumor progression, and resistance to conventional therapies. JY-GD004 is our unmodified allogeneic gamma delta T cell therapy designed for the treatment of hepatic cancer. This approach harnesses the innate tumor-targeting capabilities of γδ T cells to selectively eliminate hepatic tumor cells while modulating the immune microenvironment to enhance therapeutic efficacy. We are actively advancing JY-GD004 through preclinical and early clinical development, with the ultimate goal of providing a novel immunotherapy for hepatic cancer patients who have limited options beyond standard treatments.
JY-GD005 (Lung Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD005
Lung cancer
Lung cancer is a highly aggressive malignancy with a poor prognosis, largely due to late-stage diagnosis, rapid disease progression, and resistance to existing therapies. JY-GD005 is our unmodified allogeneic gamma delta T cell therapy designed for the treatment of lung cancer. This approach harnesses the innate tumor-targeting capabilities of γδ T cells to selectively eliminate lung tumor cells while modulating the immune microenvironment to enhance therapeutic efficacy. We are actively advancing JY-GD005 through preclinical and early clinical development, with the ultimate goal of providing a novel immunotherapy for lung cancer patients who have limited options beyond standard treatments.
JY-GD006 (Metastatic TNBC)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-GD006
Metastatic TNBC
Metastatic triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options and poor prognosis due to its high metastatic potential, lack of hormone receptor expression, and resistance to conventional therapies. JY-GD006 is our unmodified allogeneic gamma delta T cell therapy developed for the treatment of metastatic TNBC. This approach harnesses the innate tumor-targeting capabilities of γδ T cells to selectively eliminate TNBC tumor cells while modulating the immune microenvironment to enhance therapeutic efficacy. We are actively advancing JY-GD006 through preclinical and early clinical development, with the ultimate goal of providing a novel immunotherapy for metastatic TNBC patients who have limited options beyond standard treatments.